Literature DB >> 25008182

Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy.

Rachel Goldberg1, Ariel M Rubinstein1, Natali Gil1, Esther Hermano1, Jin-Ping Li2, Johan van der Vlag3, Ruth Atzmon1, Amichay Meirovitz1, Michael Elkin4.   

Abstract

Renal involvement is a major medical concern in the diabetic population, and with the global epidemic of diabetes, diabetic nephropathy (DN) became the leading cause of end-stage renal failure in the Western world. Heparanase (the only known mammalian endoglycosidase that cleaves heparan sulfate) is essentially involved in DN pathogenesis. Nevertheless, the exact mode of heparanase action in sustaining the pathology of DN remains unclear. Here we describe a previously unrecognized combinatorial circuit of heparanase-driven molecular events promoting chronic inflammation and renal injury in individuals with DN. These events are fueled by heterotypic interactions among glomerular, tubular, and immune cell compartments, as well as diabetic milieu (DM) components. We found that under diabetic conditions latent heparanase, overexpressed by glomerular cells and posttranslationally activated by cathepsin L of tubular origin, sustains continuous activation of kidney-damaging macrophages by DM components, thus creating chronic inflammatory conditions and fostering macrophage-mediated renal injury. Elucidation of the mechanism underlying the enzyme action in diabetic kidney damage is critically important for the proper design and future implementation of heparanase-targeting therapeutic interventions (which are currently under intensive development and clinical testing) in individuals with DN and perhaps other complications of diabetes.
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25008182     DOI: 10.2337/db14-0001

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  29 in total

1.  Evidence of glucuronidation of the glycation product LW-1: tentative structure and implications for the long-term complications of diabetes.

Authors:  David R Sell; Ina Nemet; Zhili Liang; Vincent M Monnier
Journal:  Glycoconj J       Date:  2018-01-05       Impact factor: 2.916

2.  Involvement of Heparanase in Empyema: Implication for Novel Therapeutic Approaches.

Authors:  Moshe Lapidot; Uri Barash; Yaniv Zohar; Yuval Geffen; Inna Naroditsky; Neta Ilan; Lael Anson Best; Israel Vlodavsky
Journal:  J Clin Cell Immunol       Date:  2015-02

Review 3.  The advancements of heparanase in fibrosis.

Authors:  Qianying Lv; Ji Zeng; Long He
Journal:  Int J Mol Epidemiol Genet       Date:  2016-11-30

4.  Diabetic nephropathy: Heparanase mediates renal injury.

Authors:  Peter Sidaway
Journal:  Nat Rev Nephrol       Date:  2014-07-29       Impact factor: 28.314

Review 5.  The Role of Heparan Sulfate in Inflammation, and the Development of Biomimetics as Anti-Inflammatory Strategies.

Authors:  Brooke L Farrugia; Megan S Lord; James Melrose; John M Whitelock
Journal:  J Histochem Cytochem       Date:  2018-01-01       Impact factor: 2.479

6.  Heparanase Upregulation Contributes to Porcine Reproductive and Respiratory Syndrome Virus Release.

Authors:  Chunhe Guo; Zhenbang Zhu; Yang Guo; Xiaoying Wang; Piao Yu; Shuqi Xiao; Yaosheng Chen; Yongchang Cao; Xiaohong Liu
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 7.  Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression.

Authors:  Sunil Rangarajan; Jillian R Richter; Robert P Richter; Shyam K Bandari; Kaushlendra Tripathi; Israel Vlodavsky; Ralph D Sanderson
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 8.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

Review 9.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

Review 10.  Biology of the Heparanase-Heparan Sulfate Axis and Its Role in Disease Pathogenesis.

Authors:  Israel Vlodavsky; Uri Barash; Hien M Nguyen; Shi-Ming Yang; Neta Ilan
Journal:  Semin Thromb Hemost       Date:  2021-04-01       Impact factor: 6.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.